Not a Member?
Email this page
Send the page ""
to a friend, relative, colleague or yourself.
Separate multiple email address with a comma
We do not record any personal information entered above.
Thank you. Your email has been sent.
Enroll today in the free PDR Pharmacy Discount Card Program and help your patients save
Megace (Bristol-Myers Squibb)
Treatment of anorexia, cachexia, or an unexplained significant weight loss in AIDS patients.
Adults: (ES) Initial: 625mg/day (5mL/day). (Megace) Initial: 800mg/day (20mL/day). Effective Dose: 400mg/day and 800mg/day. Elderly: Start at lower end of dosing range.
Sus: (ES) 125mg/mL [150mL]; (Megace) 40mg/mL [240mL]
Known or suspected pregnancy.
Institute only after treatable causes of weight loss are sought and addressed. 125mg/mL strength is not substitutable with other strengths (eg, 40mg/mL). Overt Cushing's syndrome and asymptomatic pituitary-adrenal suppression reported with chronic use. Adrenal insufficiency reported in patients receiving or being withdrawn from chronic therapy; consider use of replacement or stress doses of a rapidly acting glucocorticoid. New onset diabetes mellitus (DM) and exacerbation of preexisting DM reported with chronic use. Breakthrough bleeding reported in women. Caution with history of thromboembolic disease and in elderly.
Diarrhea, rash, flatulence, N/V, HTN, headache, pain, asthenia, insomnia, anemia, fever, decreased libido, impotence, hyperglycemia.
(ES) May decrease exposure of indinavir; consider higher dose of indinavir.
Category X, not for use in nursing.
Progesterone; has not been established. Has appetite-enhancing property.
Absorption: (800mg qd) Cmax=753ng/mL; AUC=10,476ng•hr/mL; Tmax=5 hrs (median). (750mg qd) Cmax=490ng/mL; AUC=6779ng•hr/mL; Tmax=3 hrs (median). Elimination: Urine (66.4%, 5-8% metabolites); feces (19.8%); (ES) T1/2=20-50 hrs.
Assess for preexisting DM, history of thromboembolic disease, hypersensitivity to drug, pregnancy/nursing status, and possible drug interactions.
Monitor for adrenal insufficiency, new onset/exacerbation of DM, vaginal bleeding, and other adverse reactions.
Inform about product differences to avoid overdosing or underdosing. Instruct to use ud. Advise to report any adverse reactions. Advise women of childbearing potential to use contraception while on therapy, and to notify physician if pregnancy occurs.
Administration: Oral route. Shake well before use. Storage: 15-25°C (59-77°F). Protect from heat.